Lantern Pharma (LTRN) Enterprise Value (2020 - 2026)

Lantern Pharma (LTRN) has reported Enterprise Value for 7 consecutive years, with $45.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value rose 152.2% year-over-year to $45.8 million; the trailing twelve-month figure through Jun 2026 stood at $45.8 million (up 152.2% YoY), and the FY2025 full-year result was $24.0 million, up 130.82% from the prior year.
• Enterprise Value grew to $45.8 million in Q2 2026 per LTRN's latest filing, from $9.1 million in the prior quarter.
• Across five years, Enterprise Value topped out at $56.3 million in Q1 2024 and bottomed at -$7.9 million in Q3 2023.
• Historically, Enterprise Value has averaged $15.2 million across 5 years, with a median of $11.9 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value plunged 111.57% in 2022, then jumped 6161.55% in 2024.
• Over 5 years, Enterprise Value stood at $10.4 million in 2022, then plunged by 55.84% to $4.6 million in 2023, then jumped by 126.66% to $10.4 million in 2024, then jumped by 130.82% to $24.0 million in 2025, then jumped by 91.16% to $45.8 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $45.8 million, $9.1 million, and $24.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.